Stay updated with breaking news from Research Development Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours
When: Penn Township supervisors meeting, Jan. 10.
The House Transportation Committee is considering legislation to permit personal delivery devices to one day operate on all sidewalks and crosswalks and along the side of roadways in the state.
Satellite Healthcare Participates in Clinical Trial With Home Hemodialysis Machine Effort aims to empower patients to choose home hemodialysis with confidence AUSTIN, Texas--(BUSINESS WIRE)--Satellite Healthcare today announced it will participate in an ongoing clinical trial sponsored by DEKA Research & Development Corp. (DEKA). The study is investigating the clinical use of the HemoCare® Hemodialysis System, a new home hemodialysis machine that has been designed by DEKA with a goal to make overnight hemodialysis safer and easier to perform. “Satellite Healthcare h...
Message : Required fields SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020. "2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of PH-ILD, submission of the Tyvaso DPI NDA, and the launch of our Remunity ® Pump for Remodulin ®,...